Alar Pharmaceuticals Statistics
Total Valuation
Alar Pharmaceuticals has a market cap or net worth of TWD 12.22 billion. The enterprise value is 9.78 billion.
Market Cap | 12.22B |
Enterprise Value | 9.78B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
Earnings Date | Nov 8, 2024 |
Ex-Dividend Date | Jun 5, 2024 |
Share Statistics
Alar Pharmaceuticals has 66.80 million shares outstanding. The number of shares has increased by 7.66% in one year.
Shares Outstanding | 66.80M |
Shares Change (YoY) | +7.66% |
Shares Change (QoQ) | +3.64% |
Owned by Insiders (%) | 21.68% |
Owned by Institutions (%) | 5.05% |
Float | 40.14M |
Valuation Ratios
The trailing PE ratio is 26.86 and the forward PE ratio is 234.62.
PE Ratio | 26.86 |
Forward PE | 234.62 |
PS Ratio | 23.91 |
PB Ratio | 4.92 |
P/FCF Ratio | 48.75 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.42, with an EV/FCF ratio of 39.00.
EV / Earnings | 23.41 |
EV / Sales | 20.84 |
EV / EBITDA | 25.42 |
EV / EBIT | 25.66 |
EV / FCF | 39.00 |
Financial Position
The company has a current ratio of 39.65, with a Debt / Equity ratio of 0.03.
Current Ratio | 39.65 |
Quick Ratio | 39.50 |
Debt / Equity | 0.03 |
Debt / EBITDA | 0.00 |
Debt / FCF | 0.00 |
Interest Coverage | 8,883.14 |
Financial Efficiency
Return on equity (ROE) is 28.12% and return on invested capital (ROIC) is 16.06%.
Return on Equity (ROE) | 28.12% |
Return on Assets (ROA) | 14.83% |
Return on Capital (ROIC) | 16.06% |
Revenue Per Employee | 21.33M |
Profits Per Employee | 18.99M |
Employee Count | 22 |
Asset Turnover | 0.29 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +30.25% in the last 52 weeks. The beta is 0.17, so Alar Pharmaceuticals's price volatility has been lower than the market average.
Beta (5Y) | 0.17 |
52-Week Price Change | +30.25% |
50-Day Moving Average | 203.63 |
200-Day Moving Average | 255.22 |
Relative Strength Index (RSI) | 36.98 |
Average Volume (20 Days) | 286,752 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Alar Pharmaceuticals had revenue of TWD 469.27 million and earned 417.67 million in profits. Earnings per share was 6.81.
Revenue | 469.27M |
Gross Profit | 469.27M |
Operating Income | 381.98M |
Pretax Income | 442.89M |
Net Income | 417.67M |
EBITDA | 384.33M |
EBIT | 381.98M |
Earnings Per Share (EPS) | 6.81 |
Balance Sheet
The company has 2.45 billion in cash and 759,000 in debt, giving a net cash position of 2.45 billion or 36.62 per share.
Cash & Cash Equivalents | 2.45B |
Total Debt | 759,000 |
Net Cash | 2.45B |
Net Cash Per Share | 36.62 |
Equity (Book Value) | 2.48B |
Book Value Per Share | 37.16 |
Working Capital | 2.39B |
Cash Flow
In the last 12 months, operating cash flow was 253.58 million and capital expenditures -2.84 million, giving a free cash flow of 250.74 million.
Operating Cash Flow | 253.58M |
Capital Expenditures | -2.84M |
Free Cash Flow | 250.74M |
FCF Per Share | 3.75 |
Margins
Gross margin is 100.00%, with operating and profit margins of 81.40% and 89.00%.
Gross Margin | 100.00% |
Operating Margin | 81.40% |
Pretax Margin | 94.38% |
Profit Margin | 89.00% |
EBITDA Margin | 81.90% |
EBIT Margin | 81.40% |
FCF Margin | 53.43% |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 0.79%.
Dividend Per Share | 1.50 |
Dividend Yield | 0.79% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 23.99% |
Buyback Yield | -7.66% |
Shareholder Yield | -6.87% |
Earnings Yield | 3.72% |
FCF Yield | 2.05% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |